News of Note—ILiAD Biotechnologies, Emergex and more

newspapers
In this week's news of note, Emergex picked up a universal flu vaccine grant. (Pixabay)

Here is some other vaccine news of note for the week:

> ILiAD Biotechnologies announced that the National Institute for Allergy and Infectious Diseases submitted an Investigational New Drug application to study its next-gen pertussis vaccine. Release

> U.K. biotech Emergex picked up a £979,318 ($1.32 million) grant from Innovate UK to advance universal flu vaccine work. Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> The former chief scientific officer of Moderna's vaccine division, Giuseppe Ciaramella, joined CRISPR startup Beam Therapeutics. Chemical & Engineering News article

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.